Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

Forskningsoutput: TidskriftsbidragLetter

Standard

Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. / Eskelund, Christian Winther; Albertsson-Lindblad, Alexandra; Kolstad, Arne; Laurell, Anna; Räty, Riikka; Pedersen, Lone Bredo; Geisler, Christian Hartmann; Jerkeman, Mats; Grønbæk, Kirsten.

I: Haematologica, Vol. 103, Nr. 11, 2018, s. e541-e543.

Forskningsoutput: TidskriftsbidragLetter

Harvard

APA

CBE

MLA

Vancouver

Author

Eskelund, Christian Winther ; Albertsson-Lindblad, Alexandra ; Kolstad, Arne ; Laurell, Anna ; Räty, Riikka ; Pedersen, Lone Bredo ; Geisler, Christian Hartmann ; Jerkeman, Mats ; Grønbæk, Kirsten. / Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. I: Haematologica. 2018 ; Vol. 103, Nr. 11. s. e541-e543.

RIS

TY - JOUR

T1 - Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

AU - Eskelund, Christian Winther

AU - Albertsson-Lindblad, Alexandra

AU - Kolstad, Arne

AU - Laurell, Anna

AU - Räty, Riikka

AU - Pedersen, Lone Bredo

AU - Geisler, Christian Hartmann

AU - Jerkeman, Mats

AU - Grønbæk, Kirsten

PY - 2018

Y1 - 2018

U2 - 10.3324/haematol.2018.194399

DO - 10.3324/haematol.2018.194399

M3 - Letter

VL - 103

SP - e541-e543

JO - Haematologica-The Hematology Journal

T2 - Haematologica-The Hematology Journal

JF - Haematologica-The Hematology Journal

SN - 1592-8721

IS - 11

ER -